Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study

While confirming the critical prognostic role of ELTS risk and TKI treatment and DMR duration even before TFR2, this real-life study provides further information to support the safety of a second effort to discontinue TKIs in patients with CML, as a failed first attempt does not appear to preclude a second successful one.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2026-01-21
DOI
https://doi.org/10.1002/cncr.70261
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study

Selene Grano, Giulia Cotilli, Anna Rita Scortechini, Fausto Castagnetti et al.
Cancer
Chronic Myeloid Leukemia Treatments
article

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study

Selene Grano, Giulia Cotilli, Anna Rita Scortechini, Fausto Castagnetti, Matteo Dalmazzo, Carlo Gambacorti‐Passerini, Francesca Lunghi, Maria Cristina Miggiano, Nicola Orofino, Tamara Intermesoli, Valentina Bonuomo, Luigiana Luciano, Margherita Maffioli, D. Rapezzi, Sabrina Leonetti Crescenzi, Carmen Fava, Mariella D’Adda, Fabrizio Pane, Dario Consonni, Gianni Binotto, Marianna Caramella, Giuseppe Saglio, Isabella Capodanno, Chiara Elena, Daniele Cattaneo, Massimiliano Bonifacio, Bruno Martino, Alessandra Iurlo, Luciano Levato, Emilia Scalzulli, Valentina Bellani, Gianantonio Rosti, Massimo Breccia, Mario Tiribelli
article en

Abstract

While confirming the critical prognostic role of ELTS risk and TKI treatment and DMR duration even before TFR2, this real-life study provides further information to support the safety of a second effort to discontinue TKIs in patients with CML, as a failed first attempt does not appear to preclude a second successful one.

CancerVol. 132(3)
University of Verona (IT), University of Udine (IT), University of Padua (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), Azienda Ospedaliera San Giovanni Addolorata (IT), Policlinico Umberto I (IT), Ospedale di Circolo e Fondazione Macchi (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Ospedale Maggiore (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Papa Giovanni XXIII (IT), Azienda Ospedaliera San Gerardo (IT), Federico II University Hospital (IT), A. O. Ordine Mauriziano di Torino (IT), Accademia di Belle Arti di Catanzaro (IT), Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT), Policlinico San Matteo Fondazione (IT), Ospedale San Bortolo (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Ospedale San Luigi Gonzaga (IT), Azienda Ospedaliera Ospedale Civile di Legnano (IT), University of Turin (IT), University of Milano-Bicocca (IT), University of Bologna (IT)
Openalex Percentile: Top 84%
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.